Dr. Sujuan Ba, Ph.D. (National Foundation for Cancer Research)
Dr. Ba is the President and Chief Operating Officer of the National Foundation for Cancer Research (NFCR) and is recognized as one of the “Top 300 Women Leaders in Global Health” by the Global Health Programme at the Graduate Institute of International and Development Studies. Dr. Ba oversees NFCR’s strategic directions for fundraising, financial planing, scientific direction and partnership development. Dr. Ba also serves on the Organizing Committee for the 2015 Personalized Medicine Conference, a cross-industry, cross-disciplinary panel made up of providers, payers, educators, researchers, and government agency representatives—all committed to personalized medicine. She served as a Past President (2010-2011) Board of Directors (2006-2013) and is currently a member of the Board of Advisors of the Chinese Biopharmaceutical Association–USA (Rockville, MD). She also serves on the International Consulting Committee of the China National Research Center for Translational Medicine (Shanghai). She is a member of the Scientific Advisory Board of Medelis, Inc. (Fountain Hills, AZ) and a member of the Editorial Advisory Board for The American Breast Cancer Guide and Chinese Journal of Cancer. She also served on the Membership Committee of the International Union against Cancer (Geneva). Dr. Ba is a member of BayHelix, an invitation-only organization of leaders of Chinese origin in the global life sciences and healthcare community based in San Francisco with regional offices in Shanghai and Beijing. In 2011, she was invited as one of a few business leaders to join Maryland Governor Martin O’Malley’s Trade Mission to Asia and visited China, Korea, and Vietnam with Governor O’Malley. She was also honored with an Outstanding Alumna Award by Peking University in 2005. Prior to joining NFCR, Dr. Ba was the Director of Chiral Chemistry and Fine Chemical Consulting Services at Technology Catalysts International (TCI) where she conducted market research, business evaluation, and competitive intelligence for an international clientele of major chemical and pharmaceutical companies. From 1991-1997, she was a Principal Research Chemist and then Project Manager of Technology Development and Research Planning at Arco Chemical Company (ARCO). Dr. Ba received her B.S. in radiochemistry from Peking University and her Ph.D. in chemistry from the University of Pennsylvania.
Dr. Thomas Ichim, Ph.D.
Dr. Ichim has extensive experience with stem cell therapy and cellular product development through FDA regulatory pathways. Dr. Ichim has been published in over 100 peer-reviewed publications, has over 100 patents and patent applications to his credit, and is co-editor of two oncology based text books. He is an accomplished immunologist, drug developer with numerous contributions to the biomedical sciences spanning over 16 years and has developed numerous novel therapeutics solutions primarily in oncology.
Dr. Ichim spent over 7 years as the President and Chief Scientific Officer of Medistem, developing and commercializing a novel stem cell, the Endometrial Regenerative Cell, through drug discovery, optimization, preclinical testing, IND filing, and up through Phase II clinical trials with the FDA. Subsequent to the acquisition of Medistem by Intrexon (a NYSE traded company), in a deal worth $26 million, Dr. Ichim was brought on to the parent company in its cell engineering unit as Vice President of Cellular Therapy. Dr. Ichim also serves on the Board of numerous life science companies and industry organizations.
Dr. Ichim has a BSc in Biology from the University of Waterloo, Waterloo, Ontario, Canada, an MSc in Microbiology and Immunology, University of Western Ontario, London, Ontario, Canada and a Ph.D in Immunology from the University of Sciences Arts and Technology, Olveston Monserrat.
Dr. David M. Ward, M.D., FRCP (UCSD Health System)
Dr. Ward is a Professor of Clinical Medicine, Associate Medical Director, Kidney Transplantation, and Medical Director, Apheresis Program, of the Univ. of California San Diego, Health Center. Dr. Ward's training in internal medicine together with his fellowship in nephrology (kidney disease) were at the Glasgow Royal Infirmary, in his native Scotland. This was followed by a second fellowship, in immunology and immunopathology, at the Scripps Research Foundation, La Jolla, California. He joined the UC San Diego faculty in 1977 as a nephrology clinician and researcher. His research program in immunopathology was NIH-funded for many years, and much of his laboratory work had a direct bearing on the mechanisms of diseases treated by apheresis.